FAM162A Protein Extends Lifespan and Boosts Mitochondrial Health in New Study
A newly characterized inner mitochondrial protein reshapes cristae structure, enhances energy output, and extends lifespan in transgenic flies.
Summary
FAM162A, a previously understudied inner mitochondrial membrane protein, has been found to play a central role in maintaining mitochondrial cristae structure, boosting cellular energy production, and extending lifespan. Researchers at Universidad Andres Bello used cell-based loss- and gain-of-function experiments alongside a transgenic Drosophila model to show that FAM162A interacts with OPA1, the key regulator of inner mitochondrial membrane fusion. Silencing FAM162A disrupted cristae architecture, reduced oxidative phosphorylation, and increased cell death, while overexpression had the opposite effects. Flies engineered to express human FAM162A lived longer and maintained better locomotor function under both normal conditions and heat stress, identifying FAM162A as a promising target in longevity and mitochondrial medicine.
Detailed Summary
Mitochondria are not static powerhouses — they constantly fuse, divide, and remodel their internal architecture to meet cellular energy demands and withstand stress. A central but poorly understood player in this process is FAM162A (also called HGTD-P), a protein previously known mainly for promoting apoptosis under low-oxygen conditions. This study from Elorza and colleagues in Aging Cell comprehensively maps FAM162A's physical location within the mitochondria and demonstrates its broad role in mitochondrial integrity and organismal longevity.
Using protease-protection assays in COS7 cells, the researchers placed the protein in the inner mitochondrial membrane (IMM), specifically within the cristae compartment — addressing a long-standing controversy about its precise localization, topology, and orientation.
Silencing FAM162A in COS7 cells caused mitochondrial fragmentation, reduced cristae density, and a shift toward shorter OPA1 isoforms — OPA1 being the GTPase that governs IMM fusion and cristae remodeling. Seahorse bioenergetic analysis of FAM162A-knockdown cells showed reductions in respiratory capacity, accompanied by reduced cell viability.
Conversely, FAM162A overexpression enhanced cristae architecture, shifted OPA1 toward the long (fusion-promoting) isoform, and increased bioenergetic parameters. The authors report that FAM162A interacts with OPA1 to regulate the proportion of long- and short-OPA1 isoforms, suggesting FAM162A post-translationally modulates OPA1 processing. FAM162A expression was also positively associated with OPA1 protein levels, and the protein supported mitochondrial turnover.
The most striking findings came from the transgenic Drosophila model. Flies overexpressing human FAM162A showed increased lifespan and locomotor activity compared to controls under both normal conditions and heat stress, demonstrating that the mitochondrial benefits translate into whole-organism resilience. These findings position FAM162A as a longevity-associated protein operating through the OPA1-cristae axis, with implications for aging biology, neurodegeneration, and cancer metabolism.
Key Findings
- FAM162A localizes definitively to the inner mitochondrial membrane within cristae compartments, resolving prior controversy via protease-protection assays in COS7 cells
- FAM162A knockdown caused significant mitochondrial fragmentation and reduced cristae density, with shifts toward short (fission-associated) OPA1 isoforms
- Seahorse analysis showed FAM162A silencing reduced basal respiration, ATP-linked respiration, and maximal respiratory capacity, while overexpression significantly increased all three parameters
- FAM162A co-immunoprecipitated with OPA1 and its expression level correlated positively with the long-to-short OPA1 isoform ratio, indicating post-translational regulation of OPA1 processing
- MitoTimer assays showed FAM162A knockdown increased the proportion of aged/damaged mitochondria, while overexpression reduced it, consistent with improved mitophagy
- Transgenic Drosophila ubiquitously overexpressing human FAM162A showed increased lifespan and better locomotor performance under both normal and heat stress (37°C) conditions
- FAM162A silencing increased cytochrome c cytoplasmic release and Annexin V staining, indicating enhanced apoptotic signaling, while overexpression reduced these markers
Methodology
The study used COS7 cells with siRNA-mediated knockdown (three validated siRNA constructs) and plasmid-based overexpression to perform loss- and gain-of-function experiments; mitochondrial localization was established by live-cell confocal microscopy and Western blot protease-protection assays using N- and C-terminal GFP-tagged FAM162A constructs alongside established compartmental markers. Bioenergetics were measured using Seahorse XF analysis, mitochondrial morphology by confocal microscopy, and mitochondrial age by MitoTimer fluorescence. A transgenic Drosophila melanogaster model with ubiquitous human FAM162A overexpression was generated to assess lifespan and locomotor function under normal and heat stress conditions; statistical comparisons used appropriate parametric and non-parametric tests with significance thresholds reported throughout.
Study Limitations
The in vivo longevity data come exclusively from Drosophila, and translation to mammalian or human aging remains to be demonstrated. The cell work was conducted in COS7 (African green monkey kidney) cells, which may not fully represent post-mitotic or metabolically specialized cell types most relevant to aging. The authors do not report conflicts of interest, and the study was funded by Chilean national research grants (FONDECYT) and US NIH, with no industry involvement noted.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.